Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $8 |
| % Growth | -18.6% | 40% | -78.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $1 | $7 |
| % Margin | 100% | 87.9% | 83.1% | 96.4% |
| R&D Expenses | $8 | $9 | $13 | $9 |
| G&A Expenses | $0 | $0 | $3 | $4 |
| SG&A Expenses | $2 | $2 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $10 | $11 | $16 | $12 |
| Operating Income | -$8 | -$9 | -$13 | -$4 |
| % Margin | -430.9% | -380.4% | -785.8% | -55.2% |
| Other Income/Exp. Net | -$1 | -$3 | -$1 | -$1 |
| Pre-Tax Income | -$9 | -$12 | -$14 | -$5 |
| Tax Expense | $0 | -$2 | $0 | $0 |
| Net Income | -$9 | -$10 | -$14 | -$5 |
| % Margin | -498.1% | -420.8% | -863% | -70.1% |
| EPS | -0.046 | -0.054 | -0.098 | -0.038 |
| % Growth | 15.5% | 44.9% | -158.9% | – |
| EPS Diluted | -0.046 | -0.054 | -0.098 | -0.038 |
| Weighted Avg Shares Out | 205 | 180 | 145 | 143 |
| Weighted Avg Shares Out Dil | 205 | 180 | 145 | 143 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$10 | -$16 | -$14 |
| % Margin | -494.8% | -429.7% | -983% | -174.5% |